title: Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib.
authors: Royal Marsden Hospital, London and Surrey, United Kingdom. sanjay.popat@rmh.nhs.uk
authors: Sanjay
authors: S
authors: Popat
authors: Alexandra
authors: A
authors: Vieira de Araújo
authors: Toon
authors: T
authors: Min
authors: John
authors: J
authors: Swansbury
authors: Melissa
authors: M
authors: Dainton
authors: Andrew
authors: A
authors: Wotherspoon
authors: Eric
authors: E
authors: Lim
authors: Andrew G
authors: AG
authors: Nicholson
authors: Mary E R
authors: ME
authors: O'Brien
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D000368:Aged; D000077548:Anaplastic Lymphoma Kinase; D066246:ErbB Receptors / Q000235:genetics*; D000069347:Erlotinib Hydrochloride; D005091:Exons / Q000235:genetics*; D005260:Female; D015321:Gene Rearrangement; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D009154:Mutation / Q000235:genetics*; D011799:Quinazolines / Q000627:therapeutic use*; D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics*; D016896:Treatment Outcome
chemical_list: D011799:Quinazolines; D000069347:Erlotinib Hydrochloride; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; C512478:EGFR protein, human; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases